Ev3 Inc. (Nasdaq: EVVV), a Plymouth, Minn.-based developer of catheter devices for the endovascular treatment of vascular diseases and disorders, has filed for a $175 million secondary offering of common stock. Shareholders Warburg Pincus and The Vertical Group are offering up $125 million in the deal, which would reduce their combined ownership stake from around 70% to 60 percent. www.ev3.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.